[Continuous intravenous infusion versus intermittent administration of streptokinase in patients with deep venous thrombosis of the lower extremity].

In a multicenter randomized trial, the efficacy and safety of two streptokinase (SK) dosage regimens have been evaluated in patients with proximal deep vein thrombosis of inferior limbs. Twenty-nine patients received SK by a continuous intravenous infusion (250,000 IU as initial dose, 100,000 IU/h as maintenance dose), and 26 patients were treated with intermittent SK administration (500,000 IU as initial dose, followed by 250,000 IU every 12 h). Thrombolytic therapy was continued for 4 days, then the patients received heparin for 5 days and oral anticoagulant for 3 months.

[Evaluation of the stability of vincristine binding to blood platelets by the method of spin labeling of platelet membrane].

N-(1-oxyl-2,2,6,6-tetramethylpriperyd-4-y) maleimide (MSL) labels SH or NH2 groups of blood platelets membrane proteins in covalent bonds. Then EPR spectrum of MSL labeled platelets solutions can be measured. Pre-incubation + of the platelets with vincristine prior to MSL labeling induces SH and NK2 groups blocking, decrease in MSL binding to the platelets membrane and EPR spectrum modification of labeled platelets solution.

[Use of vincristine-loaded blood platelets, danazol and gamma globulin in the treatment of patients with idiopathic thrombocytopenic purpura].

In 17 patients with idiopathic thrombocytopenic purpura unresponsive to treatment with steroids, immunosuppression or splenectomy, allogenic vincristine-loaded platelets were used. In 9 of them an increase of platelet number and regression of bleeding tendency was achieved. Among 13 patients with ITP who have been treated with danazol only in one case an increase of platelet number was observed.

Disturbances of platelet function in patients with multiple myeloma.

Coagulation disturbances in patients with multiple myeloma are presented. Platelet disfunction was especially observed, but only in patients with marked hyperproteinemia and a high level of immunoglobulins in plasma, whereas normal adhesion and aggregation were noticed in 3 out of 17 patients without protein disturbances. Chemotherapy as well as plasma exchange caused not only a decrease of the paraprotein level in plasma, but also a normalization of the failure previously observed in platelet function.

Clinical investigations on long-term activation of fibrinolysis by anabolic steroids.

The influence of anabolic steroids plus phenformin on the course of disease was studied in patients suffering from occlusive vascular diseases. In arteriosclerosis obliterans of the lower limbs the combined therapy led to a higher percentage of improvement than the control group showed. In coronary heart disease there was also a beneficial effect of this treatment.

The influence of cytostatic treatment on the initiation of plasma coagulation in patients with neoplastic diseases.

The above described changes in the haemostatic system in acute leukemias are well known and underlined by many authors [1, 5, 6, 9]. It should be stressed that the results of particular nonspecific hemostatic tests in some patients may be within the normal range in spite of significant alterations in the activity of some blood coagulation factors and the presence of hemorrhagic symptoms. In the observations of some authors the factor VIII level is distinctly increased in the majority of acute leukemic cases, whereas the vitamin K-dependent blood coagulation factors show a low activity in some patients [6, 9].

Localized intravascular coagulation in the mesenteric region.

Coagulation and fibrinolysis were measured in the portal and peripheral circulation in 15 rabbits after ligation of the superior mesenteric artery. It was found that the local coagulation syndrome in the mesenteric region can be recognized by tests in blood samples taken from the peripheral circulation area.

Prevention of experimental gastric ulcers in rats by dial derivatives.

In 111 rats divided into 5 groups, Ipronal (5-allyl-5-(beta-hydroxypropyl)-barbituric acid) protected rats from development of experimental ulceration of the gastric mucosa twice as effectively as diallylbarbituric acid and compound D2H (5-isopropyl-5-(beta-hydroxypropyl)-barbituric acid). Compound D1S (alpha-allophanyl-alpha-allyl-gamma-valerolactone) was devoid of this action.